Download PDF
Thromb Haemost 1970; 23(03): 486-499
DOI: 10.1055/s-0038-1654075
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Inhibition of Thrombin, Plasmin and Plasminogen Activation by Amidino Compounds[*]

J. D Geratz
1   Department of Pathology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

1. A series of amidino compounds have been investigated for their inhibitory effect on thrombin, plasmin and the streptokinase dependent activation of plasminogen. Diamidines composed of two amidinophenyl residues linked in para or meta position by a molecular bridge proved to be the strongest inhibitors known so far of the three enzyme systems, and they were much more active than amidines with a single-ring structure.

2. Of all the compounds tested, pentamidine was the most effective inhibitor of the hydrolysis of BANA by thrombin and plasmin. The Ki values were 9 × 10-6 M and 3.3 × 10-6 M, respectively. Inhibition was competitive in nature.

3. Pentamidine was the leading inhibitor of the fibrinolytic activity of plasmin and was approximately 83 times stronger, on a molar basis, than ε-aminocaproic acid.

4. Pentamidine also possessed the greatest inhibitory effect on the streptokinase-mediated activation of human plasminogen. On a molar basis pentamidine was 910 times more active than ε-aminocaproic acid.

5. In the thrombin clotting test, some amidines caused inhibition while others brought about an acceleration of the reaction. M & B 4596 was the strongest inhibitor affecting 50% inhibition at a concentration of 5 × 10-6 M. 2.2’-Dibromopropamidine produced the greatest augmentation of thrombin activity, raising it 167% above the control level at a concentration of 2 × 10-4 M.

6. The caseinolytic activity of thrombin again was blocked most effectively by M & B 4596. All other amidines also proved inhibitory in this assay system.

* This study was supported by U. S. Public Health Service Grants AM 10746 and HE 6350.


 

  • References

  • 1 Abiko Y, Iwamoto M, Tomikawa M. Plasminogen-plasmin system. V. A stoichiometric equilibrium complex of plasminogen and a synthetic inhibitor. Biochim. biophys. Acta (Amst.) 185: 424 1969;
    CrossrefPubMedGoogle Scholar
  • 2 Ablondi F. B, Hagan J. J, Philips M, De Renzo E. G. Inhibition of plasmin, trypsin, and the streptokinase-activated fibrinolytic system by ε-aminocaproic acid. Arch. Biochem 82: 153 1959;
    CrossrefPubMedGoogle Scholar
  • 3 Alkjaersig N, Fletcher A. P, Sherry S. ε-Aminocaproic acid: an inhibitor of plasminogen activation. J. biol. Chem 234: 832 1959;
    PubMedGoogle Scholar
  • 4 Ashley J. N, Barber N. J, Ewins A. J, Newberry G, Self A. D. H. A chemotherapeutic comparison of the trypanocidal action of some aromatic diamidines. J. chem. Soc I: 103 1942;
    CrossrefPubMedGoogle Scholar
  • 5 Ashley J. N, Harris J. O. Attempts to find new chemotherapeutic amidines. Part III. Nuclear substituted derivatives of 4,4’-and 3,3’-diamidinostilbene. J. chem. Soc II: 567 1946;
    PubMedGoogle Scholar
  • 6 Ashley J. N, Berg S. S, Lucas J. M. S. 3: 3’-Diamidinocarbanilide : a new drug against babesial infections. Nature (Lond.) 185: 461 1960;
    PubMedGoogle Scholar
  • 7 Baker B. R, Erickson E. H. Irreversible enzyme inhibitors. CXV. Proteolytic enzymes. V. Active-site-directed irreversible inhibitors of trypsin derived from p-(phenoxyalkoxy)benz-amidines with a terminal sulfonyl fluoride. J. med. Chem 11: 245 1968;
    CrossrefPubMedGoogle Scholar
  • 8 Baker B. R, Erickson E. H. Irreversible enzyme inhibitors. CXLIV. Proteolytic enzymes. VII. Additional active-site-directed irreversible inhibitors of trypsin derived from m-and p-(phenoxyalkoxy)benzamidines with a terminal sulfonyl fluoride. J. med. Chem 12: 112 1969;
    CrossrefPubMedGoogle Scholar
  • 9 Baumgarten W, Priester L. I, Stiller D. W, Duncan A. E. W, Ciminera J. L, Loeffler L. J. 4-Amin.omethylbicyclo [2.2.2]-octane-l-carboxylic acid. A new potent antifibrinolytic agent. Its evaluation by in vitro assay procedures. Thrombos. Diathes. haemorrh. (Stuttg.) 22: 263 1969;
    PubMedGoogle Scholar
  • 10 Berg S. S, Newberry G. The search for chemo therapeutic amidines. Part X. Substituted 4: 4’-diamidino-αω-diphenoxyalkanes and-diphenyl ethers. J. chem. Soc I: 642 1949;
    PubMedGoogle Scholar
  • 11 Berg S. S, Brown K. N, Hill J, Wragg W. R. A new prophylactic trypanocidal drug, 2,7-di(m-amidinophenyldiazoamino)-10-ethyl-9-phenyl-phenanthridinium chloride di HCl (M & B 4596). Nature (Lond.) 192: 367 1961;
    CrossrefPubMedGoogle Scholar
  • 12 Brit. Patent Specification 770,693. Okamoto S. et al. (patent assigned to Mitsubishi Kasei Kogyo Co., Ltd.): A composition for combating diseases associated with plasmin activation and other proteolytic action. The Patent Office, London 1957.
    PubMed
  • 13 Burstein M. Substances fibrinoplastiques et antifibrinoplastiques. Rev. Hémat 7: 587 1952;
    PubMedGoogle Scholar
  • 14 Dixon M. The determination of enzyme inhibitor constants. Biochem. J 55: 170 1953;
    CrossrefPubMedGoogle Scholar
  • 15 Erlanger B. F, Kokowsky N, Cohen W. The preparation and properties of two new chromo-genie substrates of trypsin. Arch. Biochem 95: 271 1961;
    CrossrefPubMedGoogle Scholar
  • 16 Ferry J. D, Shulman S. The conversion of fibrinogen to fibrin. I. Influence of hydroxyl compounds on clotting time and clot opacity. J. Amer. chem. Soc 71: 3198 1949;
    CrossrefPubMedGoogle Scholar
  • 17 Folin O, Ciocalteu V. Tyrosine and tryptophane determinations in proteins. J. biol. Chem 73: 627 1927;
    PubMedGoogle Scholar
  • 18 Geratz J. D. The effect of aliphatic amino acids on the activation of trypsinogen and on the stability of trypsin solutions. Biochim. biophys. Acta (Amst.) 56: 599 1962;
    CrossrefPubMedGoogle Scholar
  • 19 Geratz J. D. The inhibitory effect of ω-amino acids and guanidino acids on the activation of α-chymotrypsinogen and trypsinogen. Arch. Biochem 102: 327 1963;
    CrossrefPubMedGoogle Scholar
  • 20 Geratz J. D. p-Aminobenzamidine as inhibitor of trypsinogen activation. Experientia (Basel) 22: 13 1966;
    PubMedGoogle Scholar
  • 21 Geratz J. D. p-Amidinophenylpyruvic acid: a new highly effective inhibitor of enterokinase and trypsin. Arch. Biochem 118: 90 1967;
    CrossrefPubMedGoogle Scholar
  • 22 Geratz J. D. Synthetic inhibitors and ester substrates of pancreatic kallikrein. Experientia (Basel) 25 (04) 83 1969;
    CrossrefPubMedGoogle Scholar
  • 23 Geratz J. D. Inhibitory effect of aromatic diamidines on trypsin and enterokinase. Experientia (Basel) 25: 1254 1969;
    CrossrefPubMedGoogle Scholar
  • 24 Ivády G, Páldy L, Koltay M, Tóth G, Kovacs Z. Pneumocystis carinii pneumonia. Lancet 10: 616 1967;
    PubMedGoogle Scholar
  • 25 Iwamoto M, Abiko Y, Shimizu M. Plasminogen-plasmin system. III. Kinetics of plasminogen activation and inhibition of plasminogen-plasmin system by some synthetic inhibitors. J. Biochem 64: 759 1968;
    CrossrefPubMedGoogle Scholar
  • 26 Iwamoto M, Abiko Y. Further kinetic studies on the inhibition of fibrinolysis by synthetic inhibitors. J. Biochem 65: 821 1969;
    CrossrefPubMedGoogle Scholar
  • 27 Korsan-Bengtsen K. Influence of anions and cations with a long hydrocarbon chain on the thrombin-fibrinogen reaction. Scand. J. clin. Lab. Invest. 12 Suppl. 45 1960
    PubMedGoogle Scholar
  • 28 Koshland Jr. D. E. Conformation changes at the active site during enzyme action. Fed. Proc. 25, 719 1964
    PubMedGoogle Scholar
  • 29 Landmann H, Markwardt F, Kazmirowski H.-G, Neuland P. Zusammenhänge zwischen chemischer Konstitution und Antitrypsinwirkung bei Derivaten der 4-Aminomethyl-benzoe-säure und anderen strukturverwandten zyklischen Verbindungen. Hoppe-Seyler’s Z. physiol. Chem 50: 745 1967;
    PubMedGoogle Scholar
  • 30 Lohmann K, Markwardt F, Landmann H. Über neue Hemmstroffe der Fibrinolyse. Naturwissenschaften 50: 502 1963;
    PubMedGoogle Scholar
  • 31 Lorand L, Pule N. G. Inhibition of proteolytic enzymes by decarboxylated amino-acid derivatives. Effect of toluenesulphonyl(tosyl)-agmatine (4-toluenesulphonamidobutyl-guanidine) on thrombin and trypsin. Nature (Lond.) 190: 722 1961;
    CrossrefPubMedGoogle Scholar
  • 32 Mares-Guia M, Shaw E. Studies on the active center of trypsin. The binding of amidines and guanidines as models of the substrate side chain. J. biol. Chem 240: 1579 1965;
    PubMedGoogle Scholar
  • 33 Markwardt F, Landmann H, Hoffmann A. Über den Einfluß von p-Aminomethyl-benzoesäure auf die Aktivierung proteolytischer Fermente. Hoppe-Seyler’s Z. physiol. Chem 340: 174 1965;
    PubMedGoogle Scholar
  • 34 Markwardt F, Landmann H, Walsmann P. Comparative studies on the inhibition of trypsin, plasmin, and thrombin by derivatives of benzylamine and benzamidine. Europ. J. Biochem 6: 502 1968;
    CrossrefPubMedGoogle Scholar
  • 35 Mix H, Trettin H.-J, Gülzow M. 4-Guanidino-benzoesäure-benzylester und 4-Guanidino-benzoesäure-4’nitro-benzylester : Neue hochwirksame Trypsininhibitoren. Hoppe-Seyler’s Z. physiol. Chem 349: 1237 1968;
    PubMedGoogle Scholar
  • 36 Muramatu M, Onishi T, Makino S, Fujii S, Yamamura Y. Inhibition of fibrinolytic activity of plasmin by various synthetic inhibitors. J. Biochem 57: 450 1965;
    CrossrefPubMedGoogle Scholar
  • 37 Muramatu M, Onishi T, Makino S, Hayakumo Y, Fujii S. Inhibition of tryptic activity by various synthetic inhibitors. J. Biochem 58: 214 1965;
    CrossrefPubMedGoogle Scholar
  • 38 Muramatu M, Fujii S. Inhibitory effects of ω-guanidino acid esters on trypsin, plasmin, thrombin and plasma kallikrein. J. Biochem 64: 807 1968;
    CrossrefPubMedGoogle Scholar
  • 39 Muramatu M, Fujii S. Inhibitory effects of ω-amino acid esters on the activities of trypsin, plasmin and thrombin. J. Biochem 65: 17 1969;
    PubMedGoogle Scholar
  • 40 Okamoto S, Okamoto U. Amino-methyl-cyclohexane-carboxylic acid: AMCHA: A new potent inhibitor of the fibrinolysis. Keio J. Med 8: 211 1962;
    PubMedGoogle Scholar
  • 41 Okamoto S, Sato S, Takada Y, Okamoto U. An active stereo-isomer (trans form) of AMCHA and its antifibrinolytic (antiplasminic) action in vitro and in vivo. Keio J. Med 13: 177 1964;
    CrossrefPubMedGoogle Scholar
  • 42 Schoenbach E. B, Greenspan E. M. The pharmacology, mode of action and therapeutic potentialities of stilbamidine, pentamidine, propamidine and other aromatic diamidines-a review. Medicine 27: 327 1948;
    CrossrefPubMedGoogle Scholar
  • 43 Schwert G. W, Takenaka Y. A spectrophotometric determination of trypsin and chymotrypsin. Biochim. biophys. Acta (Amst.) 16: 570 1955;
    CrossrefPubMedGoogle Scholar
  • 44 Sgouris J. T, Inman J. K, McCall K. B, Hyndman L. A, Anderson H. D. The preparation of human fibrinolysin (plasmin). Vox Sang 5: 357 1960;
    CrossrefPubMedGoogle Scholar
  • 45 Summaria L, Hsieh B, Groskopf W. B, Bobbins K. G. Direct activation of human plasminogen by streptokinase. Proc. Soc. exp. Biol. (N. Y.) 130: 737 1969;
    CrossrefPubMedGoogle Scholar
  • 46 Takada Y, Takada A, Ambrus J. L. Comparative study of proactivators of the fibrinolysin system in three mammalian species. Thrombos. Diathes. haemorrh. (Stuttg.) 21: 594 1969;
    PubMedGoogle Scholar
  • 47 Ts’ao C. H, Kline D. L. Plasminogen activator formed by reaction of streptokinase with human plasminogen. J. appl. Physiol 26: 634 1969;
    CrossrefPubMedGoogle Scholar
  • 48 Utz J. P. Antimicrobial therapy in systemic fungal infections. Amer. J. Med 39: 826 1965;
    CrossrefPubMedGoogle Scholar
  • 49 Wagner B. H. Unpublished method.
    PubMedGoogle Scholar
  • 50 Wagner R. H, Graham J. B, Benick G. D, Brinkhous K. M. Estimation of prothrombin by the two-stage method. In: The coagulation of blood-methods of study. 105 Tocantins L. M. Ed. Grune & Stratton; New York, London: 1955
    Google Scholar